Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ocular solution for ocular use. It enhances uveoscleral outflow of aqueous humor, thereby lowering intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for ophthalmic therapies. The formulation is designed for once‑daily instillation, offering convenient management of chronic eye pressure conditions.

Iricryn (bimatoprost) is used in the prostaglandin analog class to lower intra‑ocular pressure in glaucoma‑related conditions.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent development of glaucoma. Secondary open‑angle glaucoma: decreases intra‑ocular pressure in cases secondary to other ocular conditions. Normal‑tension glaucoma: helps maintain target intra‑ocular pressure despite normal baseline levels.

Bimatoprost eye drops may cause ocular and peri‑ocular reactions, ranging from mild to serious.

Common Side Effects: - Eye redness (hyperemia) - Increased eyelash growth - Darkening of the iris - Eye irritation or foreign body sensation

Serious or Rare Side Effects: - Severe eye inflammation (uveitis) - Paradoxical increase in intra‑ocular pressure - Corneal edema or ulceration

Before prescribing Iricryn, clinicians should evaluate patient history and monitor ocular health regularly.

Baseline intra‑ocular pressure assessment: measure IOP prior to initiating therapy. Monitor iris color change: observe for gradual darkening of the iris during treatment. Avoid use in active ocular infection: postpone treatment until infection resolved. Caution with contact lens wear: advise patients to remove lenses before instillation. Discontinue if severe inflammation occurs: stop the drug and seek ophthalmologic evaluation. Store at room temperature: keep the bottle in the original packaging, protect from light and moisture.

Bimatoprost can interact with other ophthalmic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: may increase risk of ocular side effects. - Recent ocular surgery (e.g., trabeculectomy): can compromise wound healing. - Active ocular inflammation: may exacerbate the condition.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce the IOP‑lowering effect of bimatoprost. - Non‑steroidal anti‑inflammatory eye drops: monitor for additive irritation. - Systemic carbonic anhydrase inhibitors: may have additive IOP‑lowering effect, requiring IOP monitoring.